Company intelligence / Profile preview

SwiftPharma

Ghent (Gent), Oost-Vlaanderen (Flanders), Belgiumswiftpharma.eu ↗

Ownership: Private
Development stage: Preclinical

Overview

Successfully manufactured a virus inhibitor protein for preventing HIV transmission in Medace's cleanroom facility; working on biosimilar protein for reducing the cost of oncology treatments

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Recombinant proteinsvaccinesmonoclonal antibodiescytokinesenzymesantiviralsantibacterial agentshormoneshematopoietic growth factorsartificial blood substituteshuman recombinant collagen
Industry: Biotech

Drug pipeline

2 assets

SwiftPharma poliovirus vaccine

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

PlantForm CorporationPopulation CouncilNational Institutes of Health (NIH)Bio-Manguinhos (Brazil Ministry of Health)ArthrocartMedace

Beyond the preview

Go deeper on SwiftPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SwiftPharma.

Explore the full profile